Highlights Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2026 BST			5-day change	1st Jan Change
331.70 ^USD	+0.79%		+0.57%	+1.34%

05-08	Kennedy's health officials explored US ban of some widely used antidepressants, sources say	RE
05-05	Viridian eye disease drug surpasses expectations in late-stage trial; shares soar	RE

Highlights

05-04	Amgen to Invest Additional $300 Million in Puerto Rico Manufacturing Facility	MT
05-04	Amgen Inc. Announces Additional Investment In U.S. Manufacturing Network	CI
05-01	Tranche Update on Amgen Inc.'s Equity Buyback Plan announced on April 21, 2011.	CI
04-30	Amgen Posts Higher 1Q Profit, Revenue	DJ
04-30	Amgen Q1 Adjusted Earnings, Revenue Rise	MT
04-30	Earnings Flash (AMGN) Amgen Inc. Reports Q1 Revenue $8.62B, vs. FactSet Est of $8.58B	MT
04-30	(AMGN) Amgen Expects 2026 Adjusted EPS Range $21.70-$23.10, vs. FactSet Est of $22.16	MT
04-30	Earnings Flash (AMGN) Amgen Inc. Posts Q1 Adjusted EPS $5.15 per Share, vs. FactSet Est of $4.77	MT
04-30	(AMGN) Amgen Expects 2026 Revenue Range $37.1B-$38.5B, vs. FactSet Est of $37.81B	MT
04-30	Amgen sales rise 4% in first quarter, broadens weight-loss drug development	RE
04-30	Amgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug	RE
04-30	Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2026	CI
04-30	Amgen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-29	Amgen's Tavneos Proposed to be Withdrawn by US FDA's Center for Drug Evaluation and Research	MT
04-28	Paradigm Health collaborates with FDA to transform regulatory review of clinical trial data	RE
04-28	Amgen's Tavneos Proposed to Be Withdrawn by US FDA's Center for Drug Evaluation and Research	MT
04-23	Trump announces drug pricing deal with Regeneron	RE
04-10	Amgen's lung cancer drug tarlatamab wins China approval	RE
04-06	Amgen reports positive topline phase 3 results for subcutaneous tepezza in thyroid eye disease	RE
04-06	Amgen Announces Positive Topline Phase 3 Results for Subcutaneous TEPEZZA in Adults Living with Moderate-To-Severe Active Thyroid Eye Disease	CI
03-31	US FDA warns of liver injury cases tied to Amgen's rare disease drug	RE
03-30	Viridian sinks as eye disease drug disappoints on efficacy despite trial success	RE
03-28	Amgen Announces Repatha Cuts Risk Of First Major Cardiovascular Events By 31% In High-Risk Patients Without Known Significant Atherosclerosis	CI
03-28	Takeda's psoriasis pill succeeds in late-stage studies	RE
03-27	Amgen's Relapsed Small Cell Lung Cancer Drug Recommended for EU Approval	MT